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Mutations in EIF2S3, encoding the eIF2γ subunit, are associatedwith severe intellectual disability andmicroceph-
aly, usually as part of MEHMO syndrome.
Methods: Exome sequencing of the X chromosomewas performed on three related males with normal head cir-
cumferences and mild learning difﬁculties, hypopituitarism (GH and TSH deﬁciencies), and an unusual form of
glucose dysregulation. In situ hybridisation on human embryonic tissue, EIF2S3-knockdown studies in a
human pancreatic cell line, and yeast assays on the mutated corresponding eIF2γ protein, were performed in
this study.
Findings:We report a novel hemizygous EIF2S3 variant, p.Pro432Ser, in the three boys (heterozygous in their
mothers). EIF2S3 expressionwas detectable in the developing pituitary gland and pancreatic islets of Langerhans.
Cells lacking EIF2S3 had increased caspase activity/cell death. Impaired protein synthesis and relaxed start codon
selection stringency was observed in mutated yeast.
Interpretation:Our data suggest that the p.Pro432Sermutation impairs eIF2γ function leading to a relativelymild
novel phenotype compared with previous EIF2S3 mutations. Our studies support a critical role for EIF2S3 in
human hypothalamo-pituitary development and function, and glucose regulation, expanding the range of phe-
notypes associatedwith EIF2S3mutations beyond classicalMEHMO syndrome. Untreated hypoglycaemia in pre-
vious casesmay have contributed to their more severe neurological impairment and seizures in association with
impaired EIF2S3.
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EIF2S31. Introduction
The eukaryotic translation initiation factor (eIF) 2 subunit 3 (EIF2S3)
(NM_001415; Xp22.11) gene encodes the gamma (γ) subunit of the
translation initiation factor eIF2; the largest of the three eIF2 subunits.edicine Programme, UCL Great
H, United Kingdom.
pen access article under the CC BY-NIn translation initiation, eIF2 binds GTP via eIF2γ, and the initiator
methionyl-tRNA (Met-tRNAiMet), to form a ternary complex that scans
mRNA for the AUG start codon [1]. Mutations in several translation fac-
tors, including eIF2 subunits, enhance translation initiation at near cog-
nate codons such as AUU and UUG [1–3]. EIF2S3 is located within
Xp21.1-p22.13, a region linked to a rare intellectual disability (ID) disor-
der designated asMEHMO syndrome (OMIM300148) [4].MEHMO syn-
drome exhibits phenotypic heterogeneity and is variably characterized
by mental retardation, epileptic seizures, hypogonadism withC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
A non-consanguineous white European pedigree with three af-
fected male patients, presented with severe recurrent
hypoglycaemia, short stature with GH and TSH deficiencies, an
unusual form of glucose dysregulation, and mild learning difficul-
ties. This combination of phenotypes has, to date, not been re-
ported in the literature. There were no publications linking these
phenotypes in any online journal listed on Pubmed or elsewhere.
Added value of this study
Exome sequencing of the X-chromosome revealed a novel mis-
sense variant c.1294C N T in EIF2S3 (p.Pro432Ser), encoding a
subunit of the eukaryotic translation initiation factor 2, eIF2γ, in
all three male patients and in the heterozygous mothers. Muta-
tions in EIF2S3 have been described in patientswithMEHMO syn-
drome, characterized by severe intellectual disability,
microcephaly, short stature, epilepsy and accompanying midline
and facial abnormalities. The functional and expression data in
our study show a moderate but significant eIF2γ impairment,
which relates to the milder phenotype in our three male patients.
Implications of all the available evidence
This milder loss of function comparedwith previous EIF2S3muta-
tions gives rise to a phenotype that is distinct from the classical
spectrum of MEHMO syndrome. Untreated hypoglycaemia in the
previously published casesmay have contributed to their more se-
vere impairment of neurodevelopment and seizures. We highlight
that pancreatic and pituitary phenotypes appear to be associated
with EIF2S3 mutations. Early identification of such patients with
a rapid molecular diagnosis may lead to prevention of significant
morbidity, and may be critical for the prevention of significant
neurodevelopmental delay in these patients.
471L.C. Gregory et al. / EBioMedicine 42 (2019) 470–480hypogenitalism,microcephaly, and obesity. Life expectancy ranges from
b1 year-adulthood and the condition is associated with signiﬁcantmor-
bidity and mortality.
An EIF2S3 missense substitution, p.Iso222Thr, was previously re-
ported in a pedigree with three male children with MEHMO syndrome.
Clinical features included moderate-to-severe intellectual disability
(ID), microcephaly, short stature, epilepsy and facial dysmorphic fea-
tures [5]. Each affected individual had unique additional features
consisting of cleft lip/palate, behavioural problems, generalised sei-
zures, post-pubertal microgenitalism and obesity. Two patients had
growth hormone deﬁciency (GHD); however, no detailed data on pitu-
itary function were presented, as the study focused on the neurological
phenotype. Functional studies of themutation in the corresponding res-
idue in yeast eIF2γ revealed substantially impaired eIF2β binding to
eIF2γ, and impaired translation start codon selection.
Further EIF2S3mutations have been identiﬁed in patients with sim-
ilar phenotypes. A missense substitution p.Iso259Met [6], and a frame-
shift p.Iso465Serfs*4 resulted in severe ID, microcephaly, GHD and
epilepsy with additional features such as spastic quadriplegia, delayed
puberty and genital abnormalities [6,7]. The patients also manifested
hypoglycaemia, although the cause of this was unknown. A recent
study reported the EIF2S3 p.Iso465Serfs*4 in three families with
MEHMO syndrome, and a novel maternally inherited missense EIF2S3
variant, p.Ser108Arg, in an unrelated male patient with milder symp-
toms [7]. Therefore all reported mutations described in EIF2S3 have
until now been identiﬁed in MEHMO patients with cardinal phenotypicfeatures including signiﬁcant ID and microcephaly. We now report a
novel p.Pro432Ser missense EIF2S3 variant associated with partial loss
of function in three boys with a milder phenotype including hypopitu-
itarism and pancreatic dysfunction.
2. Materials and methods
2.1. DNA sequencing
The coding regions of the X-chromosome were sequenced in Pedi-
gree 1 in the Department of Genetics, University Medical Center
Utrecht, Netherlands, in collaboration with GOSgene, London UK.
Next-generation sequencing of all protein coding sequences on the
X chromosome (X-exome) was performed as previously described.
Barcoded fragment libraries were pooled in equimolar ratios and
enriched using multiplexed targeted genomic enrichment [8] with the
Demo X-exome enrichment kit (Agilent Technologies, Santa Clara, CA,
USA) and sequenced according to the SOLiD 3 Plus manual (Life Tech-
nologies, Carlsbad, CA, USA). Raw sequencing data were mapped
against the GRCh37/hg18 reference genome using a custom bioinfor-
matic pipeline based on the BWA algorithm. The percentage cut-off
for the non-reference allele (NRA) of candidate single nucleotide vari-
ants and small indels was set to 15%. The cut-off for minimum sequence
coverage was set to 10 reads. Filtering of variants that ﬁt an X-linked
dominant inheritance model was performed using non-stringent
criteria for affected males being hemizygous for the candidate causal
variant (N50% NRA). Subsequently, all common and rare polymor-
phisms present in Ensembl 65, ExAC, gnomAD or our in-house
X-exome database of ~100 samples, weremarked as known andnot fur-
ther considered for this study. The remaining variants were considered
to be novel and thus fulﬁl the criteria for an ultra-rare disease. Protein
prediction models were consulted, that use straightforward physical
and comparative considerations reﬂecting pathogenicity of a variant.
SIFT scores range from 0 (deleterious) to 1 (tolerated), whilst
Polyphen-2 scores range from 0 (benign) to 1 (damaging) respectively.
2.2. PCR and direct sequencing analysis
PCR primers were designed using the Ensembl Genome Browser
(http://www.ensembl.org/index.html), the UCSC genome browser
(https://genome.ucsc.edu/) and the Primer3 input (http://bioinfo.ut.
ee/primer3-0.4.0/). DNA was extracted from 103 patient blood samples
from our cohort and the coding regions of EIF2S3were ampliﬁed by PCR
using exon ﬂanking primers and the BIOTAQ™ DNA Polymerase kit
(Bioline) on an Eppendorf Thermocycler. PCR products were treated
with MicroClean reagent (Web Scientiﬁc). The precipitate was se-
quenced with forward and reverse respective primers using the
BigDye® Terminator v1.1 Cycle Sequencing Kit (Life Technologies Ltd)
on an Eppendorf Thermocycler. The samples were run on a 3730XL
DNA Analyzer (Applied Biosystems/Hitachi, Japan). Detailed PCR and
sequencing conditions and primer sequences are available upon re-
quest. Control databases ExAC and gnomAD were consulted.
2.3. Cell culture
A hybrid cell line (1.1B4 cells) formed by the electrofusion of a pri-
mary culture of human pancreatic islets with PANC-1, a human pancre-
atic ductal carcinoma cell line, was obtained from Public Health England
(PHE). The cells weremaintained in a humidiﬁed CO2 incubator at 37 °C
in Roswell Park Memorial Institute (RPMI) medium 1640 containing
L-glutamine (Life Technologies), supplemented with 10% fetal calf
serum (FCS) and 5% penicillin/streptomycin (penstrep). The cells were
washed in diluted Hanks Balanced Saline Solution (Gibco) (x1 HBSS),
and trypsinised with trypsin (Gibco) diluted in x1 HBSS in line with
manufacturer's instructions. Cells were passaged at N80% conﬂuence.
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GFP-IRES-Puromycin-Zeomycin plasmids (pGIPZ) (11,744 bp), re-
ferred to in this study as Clone 1–4, contained small hairpin RNA
(shRNA) cassettes targeting the EIF2S3 human gene, validated by the
UCL Cancer Institute, and 100% matched with the expected hairpin se-
quence according to the Open Biosystems library database. An addi-
tional non-silencing (NS) pGIPZ plasmid containing a scrambled
shRNA sequence was used as a control in transduction experiments.
All ﬁve plasmids have a lentiviral (LV) backbone; long terminal repeats
(LTR's) with modiﬁed U3 and a packaging signal. The pGIPZ plasmids
also contained GFP and a puromycin-resistance cassette. This enabled
the cells to be monitored for GFP expression and be puromycin-
selected following transduction (the standardmap of the pGIPZ plasmid
is available upon request). A maxiprep of each plasmid was prepared
and used in LV packaging and transduction assays.
2.5. Lentiviral packaging
LV packaging was carried out under appropriate containment by
transient co-transfection of HEK293T cells (4.0 × 105 cells/well of a 6
well plate seeded 24 h prior transfection) for each pGIPZ plasmid in du-
plicate, with 500 ng of the pGIPZ vector constructs, 333 ng of packaging
plasmid (pCMV-dR8.91), 333 ng of VSV-G envelope expressing plasmid
(pMD2.G), Fugene HD (3.5 μl/well) transfecting agent (Promega) and
opti-mem media (Thermo Fisher Scientiﬁc). Media was replaced after
24 h incubation at 37 °C, with subsequent harvesting and ﬁltering of
the vector 24 h later. Infectious titres were determined by limiting dilu-
tions of LVs on HEK293T cells. Titres were comprised between 105 and
106 transducing units/ml.
2.6. Transduction of 1.1B4 cells using packaged LV vectors for stable gene
knockdown
1.1B4 cells were seeded into 6-well plates and transduced at a mul-
tiplicity of infection (MOI) of 5, using the previously generated lentivi-
rus under strict sterile and contained conditions. Cells were incubated
at 37 °C for 72 h before media was removed. Fresh RPMI medium con-
taining 10% FCS and 5% penstrep, also used on non-transduced cells,
was supplemented with puromycin and added to the cells to positively
select the transduced cells expressing shRNA. The cells were monitored
and kept under puromycin selection for a further 10 days, trypsinised
when conﬂuent and expanded into T25cm2 ﬂasks respectively. The
cells were washed in x1 HBSS and visualised under an Olympus IX71
inverted ﬂuorescence microscope for the presence of GFP until ready
for lysing.
2.7. qPCR analysis
Cells were lysed using RNeasy lysis buffer (RLT) and RNA was ex-
tracted using the RNeasy MiniKit (Qiagen) including a DNase digestion
step using the RNase-Free DNase Set (Qiagen). The High Capacity RNA-
to-cDNA Kit (Applied Biosystems) was used to yield cDNA from each
RNA population. Fast SYBR Green Master Mix (Life Technologies) was
used in the qPCR reactions in this study. Intron ﬂanking primers for
qPCR were designed using the Universal Probe Library database
(Roche) for the target gene (EIF2S3) and the three housekeeping
genes (GAPDH, β-ACTIN and HPRT). The cDNA derived from the reverse
transcription was diluted 1:5 in all qPCR reactions and nuclease-free
water was used as the blank.
2.8. Apoptosis assay
1.1B4 cell populations were seeded into white 96-well sterile tissue
culture treated microplates with clear bottoms (PerkinElmer, Cat:
6005181), at 10,000 cells/well in 200 μl of RPMI media, and incubatedovernight at 37 °C. Cytokine mix (100 μl/well) containing 1 L-1β
(50 U/ml), TNF-α (1000 U/ml), INF-γ (1000 U/ml) was added, diluted
in media and incubated for 16 h at 37 °C, to induce caspase activity
and thus increase apoptosis in cells. Caspase-Glo 3/7 reagent (Promega,
Cat: G8090) was added at a 1:1 ratio of reagent:sample (100 μl) to each
well and incubated for 1 h at room temperature before reading the lu-
minescent signal generated on the luminometer. There were triplicate
wells of each of the following for Clone 4 (the EIF2S3 knockdown cell
line), non-transduced (NT) and NS cell populations: blank wells with
no cells and media containing cytokine mix, wells containing cells
with media without cytokine mix, and wells containing cells with cyto-
kine mix.
2.9. In situ hybridisation on human embryonic sections
Digoxigenin (DIG) RNA probes weremade using the puriﬁed pCMV-
SPORT6 vector containing full-length human wild-type (WT) EIF2S3
cDNA (IMAGE ID: 4419438) (Source Bioscience). Human embryonic tis-
sue sections were selected at Carnegie stage (CS) 16, 19, 20, 23 (equiv-
alent to gestational age 5.5, 6, 7 and 8 weeks) respectively obtained
from the Human Developmental Biology Resource (HDBR) tissue re-
source. Gene expression studieswere performedby in situ hybridisation
as previously described [9], to generate a human embryonic expression
proﬁle in the hypothalamo-pituitary (HP) region and the pancreas.
2.10. Yeast strains and plasmids
Yeast strain J515 (identical to J212 [10];MATα leu2-3,-112 ura3-52
his3 gcd11Δ::KanMX p[GCD11, URA3]) was used for eIF2γmutant analy-
sis. Mutant and WT GCD11 constructs were introduced into J515 as the
sole source of eIF2γ by plasmid shufﬂing [11]. Plasmids used in this
study are listed and include p180 [GCN4-lacZ, URA3 12], p367 [HIS4
(AUG)-lacZ, URA3 13], p391 [HIS4(UUG)-lacZ, URA3 13], pC2872 [His8-
GCD11 (eIF2γ), LEU2 10], pC5856 [His8-gcd11-I318M in pC2872 [14]],
pC5861 [His8-gcd11-S489 N-A491V in pC2872; this study] and pC5862
[His8-gcd11-S489 N-P490S-A491V in pC2872; this study].
2.11. β-galactosidase assays
For measurement of GCN4-lacZ, HIS4(UUG)-lacZ or HIS4(AUG)-lacZ
expression, overnight yeast cultures were grown in synthetic complete
(SC) medium and used to inoculate 25 ml of SC medium at OD600 =
0.25. For measurement of GCN4-lacZ, cultures were grown for 2 h (un-
treated or treated with 1 μg/ml sulfometuron methyl (SM), an inhibitor
of leucine, isoleucine, and valine biosynthesis). Cultures continued
growing for 6 h to OD600 ≤ 1 and β-galactosidase activities were deter-
mined as previously described [12,15]. For measurement of HIS4
(UUG)-lacZ andHIS4(AUG)-lacZ expression, cultureswere left untreated
and grown for 6 h to OD600 ≤ 1, followed by measurement of β-
galactosidase activities. Averages and standard deviations of β-
galactosidase activities were calculated for three independent
transformants. Statistical signiﬁcance was calculated using an ANOVA
test followed by a post hoc Tukey's test (P b 0.05).
2.12. Patient phenotypes
Three affected males, monozygotic (identical) twin brothers (III4,
III5) and their maternal cousin (III3), born to a non-consanguineous
white European pedigree, presented with severe recurrent
hypoglycaemia, short stature with GH and TSH deﬁciencies, and an
unique pancreatic phenotype (Table 1). They have an unusual form of
glucose dysregulation which ﬂuctuates between hyperinsulinaemic
hypoglycaemia and post-prandial hyperglycaemia (Table 1). They
were treated with rhGH (Fig. 1A-C), thyroxine and diazoxide together
with chlorothiazide. The latter twomedicationswere stopped as the hy-
perinsulinism resolved at 7 years of age; however, the twinsmanifested
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473L.C. Gregory et al. / EBioMedicine 42 (2019) 470–480glucose dysregulation with post-prandial hyperglycaemia and variable
fasting hypoglycaemia. Cortisol and prolactin concentrations are nor-
mal, and the twins have progressed through puberty. Endocrine data
are presented in Table 1. Additional features in the three boys include
intestinal lymphonodular hyperplasia with eosinophilic inﬁltration.
Brain Magnetic Resonance Imaging (MRI) revealed variable white mat-
ter loss and a small anterior pituitary (AP) with a normal posterior pitu-
itary (PP) and stalk in the three boys (Fig. 1D-F). In addition, hypoplasia
of the corpus callosum and ventricular asymmetry were noted in pa-
tient III3 (Fig. 1D). Severe ID and microcephaly were not present in the
boys, and all attend a mainstream school. The older twin brothers are
maintaining educational parity with their peers, although they need
some support.
2.13. Patient III3
Patient III3 was the ﬁrst born of non-identical twins via emergency
caesarean at 38 weeks gestation [birth weight 2.1 kg (−2.8 SDS)]. He
presented with poor feeding and hypoglycaemia 18 h after birth. He
had congenital heart disease in the form of total anomalous pulmonary
venous return at presentation, as well as severe gastro-oesophageal re-
ﬂux requiring Nissen fundoplication. He was diagnosed with GHD and
rhGH was commenced at 1.8 years of age. His thyroid function is cur-
rently normal. His gonadotrophin status is unknown as he is pre-
pubertal. He had a blunted testosterone response to a 3-day HCG test;
however, he was only 3 years of age when this test was performed
(Table 1). He has global developmental delay needing 1:1 support in
mainstream school, behavioural problems and mild hepatomegaly
with normal liver function. His mother presented with secondary
amenorrhoea. He is currently 8.8 years of age, with a weight of−0.2
SDS and height of−0.3 SDS, and continues to respond well to GH ther-
apy. An oral glucose tolerance test (OGTT) performed at 8 years of age
was normal with a blood glucose of 4.3 mmol/l at 2 h; however, he
had symptomatic hypoglycaemia at 3 h with a blood glucose of
2.9 mmol/L and insulin of 8.6 mU/L, suggesting glucose dysregulation
withhyperinsulinaemichypoglycaemia.Continuous glucosemonitoring
showed blood glucose concentrations ranging from 3.1–10.3 mmol/l.
Ophthalmological examination was normal.
2.14. Patients III4 and III5
Identical twin brothers were born via caesarean section at 34 weeks
gestation; patient III4 had a birth weight of 2.15 kg (−0.3 SDS), and pa-
tient III5 had a birth weight of 1.93 kg (−1.5 SDS). Initial presentation
with gastrointestinal symptoms and failure to thrive led to a diagnosis
of intestinal lymphonodular hyperplasia and eosinophilic inﬁltration.
Both patients presented with hypoglycaemic seizures at 2 years of age,
and a diagnosis of GHD was made. Both boys had a microphallus in-
creasing in size following commencement of GH treatment at
3.2 years of age. The boys also developed central hypothyroidism at
2 years of age, and were treated with thyroxine. Patient III4 had small
undescended testes, however they descended spontaneously by
2 years of age. His twin brother, III5, had normal descended testes on ini-
tial examination. The twins had feeding difﬁculties and poor weight
gain, possibly partly due to their dairy-free diet. By 4 years of age, the
brothers had delayed speech development with mild conductive hear-
ing loss, and behavioural and mild learning difﬁculties were present
by the age of 6 years. A standard clinical microarray performed in both
boyswas normal. Behavioural difﬁcultiesweremore severe in III5; how-
ever, patient III4 often had episodes of twitching, possibly related to
hypoglycaemia. Patient III4 also had hepatomegaly,myopia and a squint.
Both brothers underwent a tonsillectomy and adenoidectomy at 4 years
of age due to recurrent tonsillitis and upper airway obstruction. At
10 years of age, the brothers had impaired glucose tolerance upon test-
ing; the glucose concentrations ﬂuctuated between hypoglycaemia and
hyperglycaemia (Table 2). Subsequently, the HbA1c was elevated in
Fig. 1. Growth charts from the three affected males from Pedigree 1. (A) III3, (B) III4, (C) III5. The labelled red arrows indicate when GH treatment was commenced in the three boys
respectively. Delayed bone age in patients III3 and III4 is indicated by the cross with a dotted line to the chronological age when the measurement was taken. Parental heights are plotted
respectively. GH, growth hormone; M(c), mother's corrected height; F, father's height. MRI scans from the three affected males, III3, III4, III5. D-F: The patients have a small AP with an
otherwise structurally normal pituitary gland, indicated by the labelled white arrows respectively. (D-F) MRI images of affected patients. (D) (i-ii) Sagittal images of patient III3
showing generalised white matter loss, a small AP and a thin CC. (D) (iii) A coronal image of patient III3 showing a small AP and ventricular asymmetry with the right ventricle being
larger than the left. (E) (i) A sagittal image of patient III4 showing generalised white matter loss and a small AP. (E) (ii) A coronal image of patient III4 showing a small AP. (F) (i) A
sagittal image of patient III5 showing generalised white matter loss and a small AP. (F) (ii) A coronal image of patient III5 showing a small AP. CC, corpus callosum; AP, anterior
pituitary; WML, white matter loss; VA, ventricular asymmetry.
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13 mmol/L with insulin 33.2 mU/L in III4; HbA1C 43 mmol/mol (N20-
42), 2 h peak glucose on OGTT 13.5 mmol/L with insulin 30.5 mU/L in
III5]. Both boys had evidence of persisting hyperinsulinaemic
hypoglycaemia (fasting glucose of 2.9 mmol/L with insulin of 2.5 mU/L
in III5, blood glucose 5 h post-oral glucose load 2.7 mmol/L with insulin
10.9 mU/L in III4) at the age of 13.6 years.
Gonadotrophin secretion tested at 12 years of age was normal
(Table 1). Patient III4 had a blunted testosterone response to a 3-day
HCG test, while his brother III5 had a borderline testosterone response
(Table1).Nevertheless, both twinbrothershaveprogressed throughpu-
berty spontaneously (the most recent pubertal examination at
14.6 years showed Genitalia (G) stage 4 with testicular volumes of 12
and 25 mls in III4 and G4 with testicular volumes of 25 and 20 mls in
III5). Both brothers are growing well on rhGH [heights of 147.7 cm
(−2.07 SDS) and 147.8 cm (−2.05 SDS) for III4 and III5 respectively,
with delayed bone ages at a chronological age of 14.1 years (Fig. 1B-C].
The BMI SDS were + 1.48 for III4 and 0.57 for III5 respectively.
Their mother had osteoporosis due to secondary amenorrhoea, with
menarche at 13 years and cessation of periods at 16 years of age, afterTable 2
Glucose tolerance test in patient III4, off Diazoxide. A prolonged oral glucose tolerance test w
patient had a low basal glucose with detectable insulin. Glucose increased over time and after
(300 mins) the patient was hypoglycaemic with a detectable insulin.
Time (mins) −30 0 30 60 90
Glucose (mmol/L) 3.6 3.2 10.2 12.1 8.8
Insulin (mU/L) 5.6 4.9 21.2 21.3 19.5which she received oestrogen supplementation (CycloProgynova). In
later life she required a hysterectomy. An MRI of the brain was normal
in the mother. Maternal height was 162.9 cm and their father had a
height of 169 cm (mid-parental height: -0.34 SDS).
3. Results
3.1. Mutational analysis
The segregation of the disease phenotype in affected male individ-
uals only, was suggestive of an X-linked mode of inheritance.
Consequently, sequencing of the X chromosome in Pedigree 1 revealed
a novel hemizygous variant in EIF2S3 (ENST00000253039.8):
ChrX_24091319 C/T, c.1294C N T, p.Pro432Ser (GRCh37) in all 3 affected
males, inherited from their heterozygousmothers (sisters). This variant
is located at a highly conserved residue in the C-terminal domain of
eIF2γ across multiple species (Fig. 2B). Protein prediction models pre-
dict this variant to be deleterious (Polyphen2 = 0.971, SIFT = 0). The
EIF2S3 c.1294C N T, p.Pro432Ser variant was absent from control data-
bases including the Exome Aggregation Consortium (ExAC) (www.as performed on patient III4 at the age of 10 years, off Diazoxide treatment. At 0 min the
2 h (120 mins) the patient had a high blood glucose. Glucose then decreased and by 5 h
120 150 180 210 240 270 300
8.4 7.8 6.2 5.5 5.5 4.0 2.7
22 22 20.5 19.4 16.1 10.7 5.5
475L.C. Gregory et al. / EBioMedicine 42 (2019) 470–480exac.broadinstitute.org) and the Genome Aggregation Database 2018
(gnomAD) (www.gnomad.broadinstitute.org). Thiswas the only poten-
tial pathogenic variant identiﬁed and was considered to be the most
likely genetic cause of the disease in the patients.
3.2. EIF2S3 expression analysis using in situ hybridisation in human em-
bryos reveals expression in the developing endocrine organs
EIF2S3mRNA transcripts were visualised in the hypothalamus and
Rathke's pouch, both the AP and PP, the progenitor cells of the nasal ep-
ithelium, and the retina of the eye at both CS20 and 23 of human devel-
opment respectively (Fig. 3A(i-iv)). The EIF2S3 transcripts were also
strongly detected in the pancreas of a 13-week old human fetus
(Fig. 3A v, vi). The EIF2S3 DIG-labelled sense control probe had negative
staining.
3.3. Cohort screening
Upon identiﬁcationof the EIF2S3 (p.Pro432Ser) variant in Pedigree 1,
103patientswithvariable congenital hypopituitarismphenotypes,+/−
structural midline brain defects on MRI, were screened for EIF2S3 vari-
ants; isolated GHD (n = 16), SOD (n = 37), hypogonadotropic
hypogonadism/Kallmann syndrome(n=4), andmultiple pituitary hor-
mone deﬁciencieswith variable endocrine deﬁcits and no othermidline
defects (n= 46). No further variants were identiﬁed in these patients.
However, there were no other patients in this cohort that had glucose
dysregulation similar to that observed in Pedigree 1.
4. Functional analysis
4.1. Generation of an EIF2S3 knockdown human pancreatic β cell line
A stable EIF2S3 knockdown (KD) cell line was established in a
human hybrid pancreatic β cell line, 1.1B4 cells, using (LV) expressing
target-speciﬁc short hairpin RNA (shRNA) and green ﬂuorescent pro-
tein (GFP). Seventy-two hours after transduction the cells ﬂuoresced
green, indicating successful transduction with shRNA-encoding LV.
The qPCR expression analysis showed that the most efﬁcient shRNA
construct (Clone 4) knocked down EIF2S3 gene expression by 82%,Fig. 2. (A) Pedigree 1 harbouring the EIF2S3 (p.Pro432Ser) variant. This pedigree consists
represented by the black shaded squares labelled with ‘EIF2S3 p.Pro432Ser’. Patients III4 and II
variant in heterozygous form. Unshaded squares/circles represent males and females that w
depict the generation within the pedigree. The numbers ‘1’ – ‘5’ distinguish between each ind
substituted eIF2γ residue. Conservation of the P432 amino acid (highlighted in green) that is
are highlighted in red (only in the yeast sequence). The surrounding protein sequence in eIF2γwith a relative quantiﬁcation (RQ) of 0.186 and a 95% conﬁdence inter-
val (CI) ranging between 0.127 and 0.274 when compared to non-
transduced cells (RQ: 1, CI: 0.89–1.124) (Fig. 3B).
4.2. Apoptosis assays in the EIF2S3 knockdown cell line demonstrate higher
caspase activity and cell death
Following transduction of 1.1B4 cells using shRNA Clone 4, cell via-
bility appeared to be reduced on visual observation. Signiﬁcantly higher
caspase activity was observed in both the KD (Clone 4) and NT control
cell populations after the addition of cytokines, compared to basal
[Clone 4 (2288 ± 358.31 versus (vs) 1203 ± 63.52 p = 0.0067) and
NT (758 ± 84.06 vs 230 ± 59.76 p= 0.0009)] (Fig. 4). Though the NS
shRNA transduced control cell population did not reach a statistically
signiﬁcant difference in caspase activity after the addition of cytokines,
it followed a similar trend to the other cell populations. Consistent
with the essential role of the translational apparatus in cell viability,
there was signiﬁcantly higher caspase activity in the clone 4 EIF2S3 KD
cells compared to the two control populations, both basally [NS 1203
± 63.52 vs 258 ± 100.49, p = 0.00016 and NT 1203 ± 63.52 vs 230
± 59.76, p= 0.00004] and after the addition of cytokines [NS 2288 ±
358.31 vs 468 ± 261.10, p = 0.002 and NT 2288 ± 358.31 vs 758 ±
84.06, p = 0.002] respectively (Fig. 4).
4.3. Altered translational control and start codon selection stringency in
EIF2S3 mutant yeast
As there are no protein structure data available for the human
eIF2 complex or the isolated human eIF2γ protein, the yeast
(Saccharomyces cerevisiae) structure presents the best current model
of the eIF2 complex [16]. The eIF2α docks on domain II of eIF2γ and
the acceptor arm of Met-tRNAiMet binds into a groove between the G do-
main and domains II and III of eIF2γ (Fig. 5A-C). The yeast P490 residue
(homologous to human Pro432) lies on a β-strand within domain III of
eIF2γ. To test if the Pro432Ser mutation impairs eIF2 function, the mu-
tation was introduced into the yeast GCD11 gene encoding eIF2γ [17].
As the residues ﬂanking the mutated Pro residue differ between yeast
and human, a locally humanized version of yeast eIF2γ was generated
by replacing Ser489 and Ala491 with Asn and Val, respectively, toof three affected individuals that are hemizygous for the EIF2S3 (p.Pro432Ser) variant,
I5 are monozygotic twins. The circles containing a dot highlight the females that carry the
ere negative for the variant respectively. The roman numerals on the left of the image
ividual within that generation, which are referred to in the text. (B) Conservation of the
substituted in Pedigree 1. Amino acids that differ from the human WT protein sequence
is very highly conserved across multiple species.
Fig. 3. (A) Human EIF2S3 expression in the hypothalamo-pituitary axis, eye and pancreas in the developing human embryo. In situ hybridization using the antisense probe against
the human EIF2S3mRNA transcript (hEIF2S3) on human sections. Expression is representative of two embryos. The scale bars represent 200 μM in (i-v), and 100 μM in (vi). (i - iii)
Transverse sections of the brain, (i) mRNA EIF2S3 transcripts were localised to the ventral hypothalamus and Rathke's pouch (CS20). (ii) EIF2S3 expression was seen in the AP and PP
although not throughout the whole pituitary tissue (CS23). (iii) Deﬁned EIF2S3 transcripts were seen in progenitor cells in the nasal epithelium (CS23). (iv) Sagittal section of the eye.
EIF2S3 transcripts were localised in the retina (CS23). (v-vi) Sagittal sections from a pancreas obtained from a 13 week old fetus, showing expression of the EIF2S3 transcript in the
Islets of Langerhans. Abbreviations: Hyp, hypothalamus; RP, Rathke's pouch; AP, anterior pituitary; PP, posterior pituitary; NE, nasal epithelium; R, retina. (B) EIF2S3 qPCR expression
analysis. (i) Histogram showing the relative quantiﬁcation (RQ) of EIF2S3 expression (shown as a percentage), against GAPDH, β-ACTIN and HPRT in cDNA derived from transduced
1.1B4 cells, compared to non-transduced cells. This non-transduced control population is thus termed as having 100% EIF2S3 expression. There are ﬁve different cDNA populations
derived from cells transduced with different shRNA cassette-containing constructs: Non-silencing Scrambled, Clone 1, Clone 2, Clone 3, Clone 4. Error bars depict the lowest
percentage value on the minus and the highest percentage value on the plus error bar respectively, generated by StepOne Real-Time PCR System software (ThermoFisher Scientiﬁc).
(ii) Table showing qPCR Relative Quantiﬁcation (RQ) values for EIF2S3 expression against GAPDH, β-ACTIN and HPRT compared to non-transduced cDNA, with a 95% conﬁdence
interval range: minimum RQ and maximum RQ, for all ﬁve cDNA populations.
476 L.C. Gregory et al. / EBioMedicine 42 (2019) 470–480mimic human eIF2γ (Fig. 2B). When expressed in yeast cells, the hu-
manized eIF2γ-S489 N-A491V mutant and the patient eIF2γ-S489 N-
P490S-A491V mutant derivative had no signiﬁcant effect on yeast cell
growth.
A more sensitive assay to examine eIF2 function in yeast relies on
translational control of the GCN4 gene [18]. Conditions that lower eIF2
ternary complex levels, like phosphorylation of eIF2α or mutations
that impair eIF2 function [1–3,10,19], elevate GCN4 expression. A
GCN4-lacZ reporter was introduced into isogenic strains expressing
WT eIF2γ, humanized eIF2γ-S489 N,A491V, the humanized mutant
eIF2γ-S489 N,P490S,A491V or eIF2γ-I318M corresponding to the pub-
lished eIF2γ-Iso259Met mutation [6]. As shown in Fig. 5D, GCN4-lacZ
expression was low in cells expressing WT eIF2γ or humanized eIF2γ-
S489 N,A491V. The p.P490S mutation resulted in a modest, but statisti-
cally signiﬁcant, ~1.7-fold increase in GCN-lacZ expression, while the
I318M mutation [7] conferred nearly an 11-fold increase in GCN4-lacZ
expression. Treatment with SM to activate eIF2α phosphorylation and
lower eIF2 ternary complex levels [20], resulted in a ~6-fold increase
in GCN4-lacZ expression in cells expressing WT eIF2γ, while GCN4-lacZ
expression was de-repressed nearly 9-fold in cells expressing the
eIF2γ-S489 N,P490S,A491Vmutant and over 20-fold in cells expressing
the eIF2γ-I318Mmutant (Fig. 5D).
Mutations in yeast eIF2 subunits that impair Met-tRNAiMet binding,
enhance GTP hydrolysis, or disrupt complex integrity have been found
to relax the stringency of translation start site selection and enhance ini-
tiation at differing codons [7,8]. To characterise mutations in thiscontext, a set of HIS4-lacZ reporter constructs with an AUG or UUG
start codon were introduced into strains expressing eIF2γWT or mu-
tant. In eIF2γWT, the HIS4(UUG)-lacZ reporter was expressed at ~1.6%
the level observed with the canonical HIS4(AUG)-lacZ reporter
(Fig. 5E) consistent with previous reports [3,13]. A similar low level of
UUG initiation was observed in cells expressing the humanized eIF2γ-
S489 N,A491V mutant (Fig. 5E, middle bar). Introduction of the P490S
mutation, however, increased HIS4(UUG)-lacZ expression to 3% of the
value obtained with the AUG-initiated reporter (Fig. 5E, third bar).
5. Discussion
Wehave identiﬁed a novel EIF2S3mutation in childrenmanifesting a
phenotype characterized by mild learning difﬁculties, hypopituitarism
with GH and TSH deﬁciencies, and an unusual form of glucose dysregu-
lation with early hypoglycaemia and later hyperglycaemia [9]. The
‘probability of loss-of-function (LoF) intolerance’ (pLI) value for EIF2S3
is 0.92, (calculated from controls in ExAC. A pLI ≥ 0.9 value is an ex-
tremely LoF intolerant gene). The observed number of missense vari-
ants from population genetic data is signiﬁcantly lower than expected
with a Z score of 3.81 (ExAC). Positive Z scores indicate intolerance to
variation, thus indicating that EIF2S3 is highly intolerant to protein cod-
ing variation. The p.Pro432Ser variant alters a highly conserved residue
in the eIF2γ C-terminal domain (Fig. 2B) and segregates in an X-linked
recessive manner in three generations of Pedigree 1 (Fig. 2A), having
been inherited from the heterozygous maternal grandmother.
Fig. 4. Apoptosis assay comparing caspase activity in EIF2S3KDcells compared to controls, with andwithout cytokine treatment. Results from anapoptosis assay shown as themean
±SDof 3 independent experimentswith each assay performed in triplicate, onNT1.1B4 cells, NS shRNA transduced 1.1B4 cells and EIF2S3KD(Clone4) 1.1B4 cells. The statistical test used
when analysing data signiﬁcance was an unpaired 2-tailed t-test. Caspase activity ismeasured as luciferase values on a luminometer. Caspase activity is signiﬁcantly higher after cytokine
treatment compared to the basal caspase activity in Clone 4 (2288 ± 358.31 versus (vs) 1203 ± 63.52, p= 0.0067) and NT (758 ± 84.06 vs 230 ± 59.76 p= 0.0009) cell populations
respectively. Basal caspase activity is signiﬁcantly higher in Clone 4 compared with NS (1203 ± 63.52 vs 258 ± 100.49, p= 0.00016; displayed in orange) and NT (1203 ± 63.52 vs
230 ± 59.76 p = 0.00004; displayed in blue) respectively. Clone 4 cells treated with cytokine mix have a signiﬁcantly higher caspase activity compared with NS (2288 ± 358.31 vs
468± 261.10 p=0.002; displayed in green) and NT (2288± 358.31 vs 758± 84.06 p= 0.002; displayed in red) cytokine-treated cell populations respectively. The error bars represent
the standard deviation (SD) of the mean. NS, scrambled non-silencing; NT, non-transduced.
477L.C. Gregory et al. / EBioMedicine 42 (2019) 470–480Murine Eif2s3 expression in the pancreas, hypothalamus and pitui-
tary (Mouse Genome Informatics), the abundant human EIF2S3 expres-
sion in the postnatal brain and endocrine tissues, and high eIF2γ protein
expression in the postnatal brain and pancreas (Human Protein Atlas)
have previously been established. Prominent EIF2S3 expression in the
hypothalamus, Rathke's pouch, AP, PP, progenitor cells of the nasal epi-
thelium, and retina of the eye (Fig. 3A(i-iv)) at CS20 and 23 has been
established in this study. At CS23, the retina is in the process of differen-
tiating into different cell types. The expression appears to be most
prominent in the developing inner nuclear layer, in a region consistent
with developing ganglion cells (Fig. 3A(iv)). However, ophthalmologi-
cal examination has revealed no retinal changes in the three boys. We
further examined expression in the human pancreas, due to the previ-
ously documented expression of murine Eif2s3 in the pancreas (MGI),
the presence of an unusual pancreatic phenotype in the patients in Ped-
igree 1, and the early onset diabetes in previously published cases. Ex-
pression was most prominent in β cell progenitors within the Islets of
Langerhans in the pancreatic tissue of a 13-week old fetus (Fig. 3A
(v-vi)). These data provide a human embryonic EIF2S3 gene expression
proﬁle in a developmental context.
The 1.1B4 human hybrid pancreatic cells [21–23] were used to per-
form a stable knockdown of the EIF2S3 gene, using an integrative LV
vector expressing EIF2S3-targeting shRNA to generate an EIF2S3 KD
cell line. The cells transduced with LV vector encoding EIF2S3-
targeting shRNA failed to survive for as long as control cell populations
(Fig. 4). Furthermore, the EIF2S3 KD cell line had signiﬁcantly higher
basal and cytokine-stimulated caspase activities compared to control
cells (Fig. 4), suggesting increased apoptosis. The impaired cell survival
and increased caspase activities in our EIF2S3 KD human cell line in this
study is consistent with the essential role of eIF2γ in initiating protein
synthesis within the cell [24].
eIF2α phosphorylation inhibits global protein synthesis under con-
ditions of endoplasmic reticulum (ER) stress [25]. In vivo, eIF2α phos-
phorylation is essential for the pancreas and liver to provide glucose
homeostasis. Defects in eIF2-mediated translational control in the pan-
creas can cause a β-cell deﬁciency and contribute to diabetes. Micewitha homozygous mutation p.Ser51Ala that abolishes phosphorylation of
eIF2α died within 18 h of birth due to prolonged hypoglycaemia associ-
ated with reduced glycogen stores and defective gluconeogenesis [26].
Homozygousmutant embryos andneonates displayed a reduction in in-
sulin content 50% and 35% that of WT mice respectively; neonates had
20% of WT serum insulin concentrations, and both had pancreatic β
cell deﬁciency [26]. A subtle reduction in eIF2α phosphorylation in het-
erozygous p.Ser51Ala mice leads to an increase in β cell death in some
treated cells [27] and type 2 diabetes when the animals are stressed
by a physiologically relevant high fat diet (HFD). Delayed folding and/
or misfolding of proinsulin in the HFD-fed mutant islets was associated
with reduced production of mature insulin [28]. These studies are con-
sistent with the glucose dysregulation observed in Pedigree 1, and sug-
gest that eIF2γmay also contribute to glucose homeostasis in humans.
The yeast assays conducted in this study show a modest increase in
GCN4-lacZ expression in the p.Pro432Ser yeast homologue (p.
Pro490Ser), compared to the robust increase in the yeast model of the
human p.Iso259Met mutation (p.Iso318Met) [14] (Fig. 5D) associated
with a more severe phenotype [6], indicating a defect in ternary
complex formation or delivery of Met-tRNAiMet to the ribosome. These
modest impacts on GCN4-lacZ expression, and the ~2-fold increase in
non-AUG initiation seenwith p.Pro490Ser (Fig. 5E) suggesting a relaxed
start site selection stringency, are comparable to previously reported
yeast assays on the human MEHMO syndrome mutations p.Iso222Thr
and Iso465Serfs*4 [5,7]. Cumulatively, our results demonstrate that
the human p.Pro432Ser eIF2γmodestly impairs eIF2 function and may
cause disease by altering the ﬁdelity of translation start site selection.
The patients in our study exhibited hypoketotic hypofattyacidaemic
hyperinsulinaemic hypoglycaemia. The pathogenesis underlying the
hypoglycaemia observed in previous patients was not established [6].
The C-terminal location of the variants and the phenotypes
encompassing GHD and hypoglycaemia described by Moortgat et al.
support the pathogenicity of EIF2S3 (p.Pro432Ser) in our phenotypically
similar patients. Previous reports describing EIF2S3mutations have fo-
cussed on ID with microcephaly [5–7]; however, two previously pub-
lished patients carrying the EIF2S3 frameshift p.Iso465Serfs*4 [7] were
Fig. 5. The p.P490S mutation in yeast eIF2γ, corresponding to the human eIF2γ-Pro432Ser mutation, impairs translation initiation. (A) Ribbon and sphere representation of
Saccharomyces cerevisiae eIF2–GDPNP–Met-tRNAiMet ternary complex (PDB code 3JAP [16] using PyMOL software (Schrodinger)). Components are coloured as follows: tRNAiMet, green
spheres; Met, grey spheres; eIF2α, yellow ribbons; eIF2β, blue ribbons; and eIF2γ, cyan ribbons. (B) Rotation of the eIF2–GDPNP–Met-tRNAiMet ternary complex to highlight the site of
the EIF2S3 patient mutation identiﬁed in this study, ScP490 (HsP432, burgundy). (C)Magniﬁcation of the eIF2–GDPNP–Met-tRNAiMet ternary complex from panel B. The three domains
of eIF2γ are indicated, and the sites of ﬁve mutations identiﬁed in patients with MEHMO syndrome or its variants are highlighted in stick representation including ScP490 (HsP432,
burgundy), a C-terminal frameshift mutation (C-term, orange), ScV281 (HsI222, magenta), ScD167 (HsS108, red), and ScI318 (HsI259, blue). (D-E) A GCN4-lacZ reporter (D) or HIS4
(AUG)-lacZ and HIS4(UUG)-lacZ reporters (E) were introduced into yeast strains containing the indicated WT or mutant forms of eIF2γ. Means and standard deviations of β-
galactosidase activities were calculated for three independent transformants. The asterisk (*) and hashtag (#) indicate a signiﬁcant difference fromWT eIF2γ in the No Treatment and
SM treatment conditions, respectively.
478 L.C. Gregory et al. / EBioMedicine 42 (2019) 470–480re-evaluated for the presence of a pancreatic phenotype. Neonatal
hypoglycaemia, early onset insulin-dependent diabetes, and variable
hypopituitarism have since been noted in some of these patients [29].
However, the cause of the neonatal hypoglycaemia has not, to date,
been established. Our studies clearly show impaired glucose dysregula-
tion with initial hypoglycaemia due to hyperinsulinism, followed by an
unusual form of diabetes that occurs in the second decade of life and is
not insulin-dependent, unlike the early onset diabetes reported in two
previously published cases [6,29]. The affected males in Pedigree 1 in
our study differ from all previously described cases in having a much
milder neurodevelopmental phenotype, with the twin boys attending
a mainstream school. Our patients do not have microcephaly, epilepsy,
or obesity which are prominent phenotypes in previous patients diag-
nosed with MEHMO syndrome [5] (Table 3). Patients III3, III4 and III5
from Pedigree 1 had variable generalised white matter loss in the
brain, ﬁndings which are consistent with previously published reports,
where patients with EIF2S3 mutations manifested a global reduction
in white matter on MRI [6]. However, this may be attributable to
hypoketotic hypoglycaemia at birth. Intriguingly, white matter loss is
a prominent feature of Vanishing White Matter (VWM) disease, in
which patients have mutations in eIF2B [30,31], the guanine-
nucleotide exchange factor for eIF2. Thus, mutations impairing eIF2
and eIF2B may display some phenotypic overlap [9].
We have shown, for the ﬁrst time to our knowledge, that the
hypoglycaemia observed in our pedigree, and likely those previously
published, is associated with hyperinsulinism (Table 3), and may then
be followed by the evolution of non-autoimmune diabetes, as shown
in a previously published murine model [32]. The signiﬁcantly higherapoptosis in the EIF2S3 KD human cell line, the human HP and pancre-
atic expression proﬁle, the yeast assays, and the segregation of the
EIF2S3 (p.Pro432Ser) variant with the hypopituitarism and glucose dys-
regulation phenotype in Pedigree 1, all suggest that the p.Pro432Ser
mutation moderately, but signiﬁcantly, impairs eIF2γ function and
leads to a relatively mild phenotype affecting human HP and pancreatic
function [9]. This milder loss of function comparedwith previous EIF2S3
mutations, gives rise to a phenotype that is distinct from the classical
spectrum of MEHMO syndrome.
Variable effects on brain development are clearly associated with
mutations in EIF2S3. It is worth considering that untreated hypoketotic
hypoglycaemia in the previously published cases may have contributed
to their more severe impairment of neurodevelopment and seizures.
The insights provided by our study reporting both pancreatic and pitu-
itary phenotypes associated with EIF2S3mutations may be critical for
the prevention of signiﬁcant neurodevelopmental delay in these pa-
tients. Early identiﬁcation of such patients with a rapid molecular diag-
nosis may lead to prevention of signiﬁcant morbidity in these patients.
The identiﬁcation of further patients with EIF2S3mutations will allow
more genotype-phenotype correlation studies that will shed further
light on the role of eIF2γ in brain, HP, and pancreatic development
and function in humans.
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Table 3
Clinical phenotypes of male patients with EIF2S3mutations from four separate studies. Clinical phenotypes from previous reports by Borck et al 5, Moortgat et al 6, Skopkova et al 7,
Stanik J et al 29, and from this current study, respectively. Not all unique additional features listed under each studywere present in every patient described; eachmalewithin the study had
various combinations of these features.
Borck et al. 2012 Mol Cell Moortgat et al. 2016 AJMG Skopkova et al. 2017 HumMutat,
Stanik J et al. 2018 Physiol Res
This study – Pedigree 1
EIF2S3, p.Iso222Thr in the highly
conserved GTP-binding (G)
domain
EIF2S3, p.Iso259Met and p.Iso465Serfs*4 in
two unrelated pedigrees in the C-terminal
domain
EIF2S3, p.Iso465Serfs*4 and
pSer108Arg in four unrelated
pedigrees
EIF2S3, p.Pro432Ser in the C-terminal domain
Three males: 2 brothers and
maternal uncle
• Intellectual disability
(moderate to severe)
• Microcephaly
• Short stature with GHD in two
patients
• Facial dysmorphic features
• Epilepsy
• Thin corpus callosum on MRI
• Enlarged lateral ventricles on
MRI
Three males: 2 brothers, 1 unrelated male
• Severe intellectual disability
• Microcephaly
• GHD
• Hypoglycaemia
• Epilepsy
• Thin corpus callosum on MRI
• Normal pituitary and stalk on MRI
• Global white matter loss on MRI
Four unrelated male patients:
• Microcephaly
• Seizures
• Hypotonia (axial)
• Hypertonia (peripheral)
• Hypogonadism
• Developmental delay
• Obesity (Infancy onset)
Three males: 2 brothers and maternal male cousin
• GHD
• Central hypothyroidism
• Unique pancreatic phenotype: ﬂuctuation between
hyperinsulinaemic hypoglycaemia and
hyperglycaemia
• Small anterior pituitary on MRI
• Thin corpus callosum on MRI
• Generalised white matter loss on MRIThe three unrelated males with
severe MEHMO syndrome only:
• Seizures
• Growth retardation
• Neonatal hypoglycaemia
(2 patients only)
• Early onset insulin-dependent
diabetes
• Variable hypopituitarism
Unique additional features:
Cleft lip/palate
• Behavioural problems
• Postpubertal microgenitalism
• Obesity
Unique additional features:
Spastic quadriplegia
• Convergent strabismus
• Delayed puberty
• Genital abnormalities
• Micrognathia (undersized jaw)
• Hypotonia
• Global reduction of white matter on MRI
Unique additional features:
• Atrial septal defect
• Severe combined
dyslipidaemia
• facial telangiectasia
• Chronic lung disease
• Congenital scoliosis
• Dysphagia
Unique additional features:
• Developmental delay
• Behavioural problems
• Micropenis
• Undescended testes
• Severe eczema
• Convergent squint
• Generalised white matter loss on MRI
• Ventricular asymmetry on MRI
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